DE69611343D1 - Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einem Hautpflegemittel - Google Patents

Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einem Hautpflegemittel

Info

Publication number
DE69611343D1
DE69611343D1 DE69611343T DE69611343T DE69611343D1 DE 69611343 D1 DE69611343 D1 DE 69611343D1 DE 69611343 T DE69611343 T DE 69611343T DE 69611343 T DE69611343 T DE 69611343T DE 69611343 D1 DE69611343 D1 DE 69611343D1
Authority
DE
Germany
Prior art keywords
yttrium
barium
manganese
cobalt
tin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69611343T
Other languages
English (en)
Other versions
DE69611343T2 (de
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of DE69611343D1 publication Critical patent/DE69611343D1/de
Application granted granted Critical
Publication of DE69611343T2 publication Critical patent/DE69611343T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/244Lanthanides; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69611343T 1995-10-26 1996-10-14 Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einem Hautpflegemittel Expired - Fee Related DE69611343T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512656A FR2740341B1 (fr) 1995-10-26 1995-10-26 Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau

Publications (2)

Publication Number Publication Date
DE69611343D1 true DE69611343D1 (de) 2001-02-01
DE69611343T2 DE69611343T2 (de) 2001-04-26

Family

ID=9483957

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69611343T Expired - Fee Related DE69611343T2 (de) 1995-10-26 1996-10-14 Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einem Hautpflegemittel

Country Status (9)

Country Link
US (1) US5866168A (de)
EP (1) EP0775492B1 (de)
JP (1) JPH09169657A (de)
AT (1) ATE198276T1 (de)
CA (1) CA2188688C (de)
DE (1) DE69611343T2 (de)
ES (1) ES2155179T3 (de)
FR (1) FR2740341B1 (de)
NO (1) NO319503B1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2740340B1 (fr) * 1995-10-30 1997-12-05 Oreal Utilisation d'acides carboxyliques porteurs d'une fonction soufree pour favoriser la desquamation de la peau ou stimuler le renouvellement epidermique
US6168798B1 (en) * 1997-02-03 2001-01-02 Bristol-Myers Squibb Company Non-irritating composition for treating acne and other skin conditions
US6248370B1 (en) * 1997-07-24 2001-06-19 Leroy Harris Skin treatment and methods
AT405017B (de) * 1997-10-06 1999-04-26 Jakoby Marie Luise Mittel zur stimulation der körpereigenen abwehr
FR2774285B1 (fr) * 1998-02-03 2001-06-15 Roche Posay Lab Pharma Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
WO2001003712A1 (en) * 1999-07-09 2001-01-18 Astion Development Aps Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement
DE10043466A1 (de) * 2000-09-04 2002-03-28 Johannes Wohlrab Manganverbindungen enthaltende Zubereitung zur topischen Applikation und deren Verwendungen
ES2181586B1 (es) * 2001-05-03 2004-06-16 Alfonso Blanco Cobo Producto farmaceutico para el tratamiento de tumores cancerigenos.
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
JP2005527601A (ja) * 2002-04-30 2005-09-15 久光製薬株式会社 二糖類及び金属イオンによる、刺激の阻止のための方法及び組成物
US7081247B2 (en) * 2002-05-20 2006-07-25 Nidaria Technology Ltd. Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
FR2846558B1 (fr) * 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
AU2002365172A1 (en) * 2002-12-09 2004-06-30 Evgeny Nikolaevich Ananiev Pharmaceutical or cosmetic composition, preventing or reducing itch and local reaction from stings of insects
EP2995312A1 (de) * 2003-03-27 2016-03-16 SantoSolve AS Entzündungshemmende zusammensetzung auf der basis von strontiumverbindungen
ATE342722T1 (de) * 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
AU2004237438B2 (en) * 2003-05-07 2011-01-20 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
WO2005009352A2 (en) * 2003-07-17 2005-02-03 The Trustees Of Columbia University In The City Of New York Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
EP1523985B1 (de) * 2003-10-17 2010-03-10 Oy Neurofood Ab Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
WO2005053613A2 (en) * 2003-11-26 2005-06-16 Combinatorx, Inc. Combinations for the treatment of fungal infections
US7258875B2 (en) * 2003-12-04 2007-08-21 Chiou Consulting, Inc. Compositions and methods for topical treatment of skin infection
FR2866810B1 (fr) * 2004-03-01 2006-04-28 Oreal Utilisation d'au moins un inhibiteur des canaux calciques pour prevenir et/ou traiter la peau grasse.
GB0517043D0 (en) * 2005-08-19 2005-09-28 York Pharma Plc Improvements in pharmaceutical compositions
US20070154448A1 (en) 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
JP2010501551A (ja) * 2006-08-25 2010-01-21 テウン イーエルエス インコーポレイテッド 毛髪改善のための希土類元素の用途
KR100769260B1 (ko) * 2006-08-25 2007-10-22 주식회사 태웅이엘에스 희토원소를 함유하는 모발 개선용 조성물
GB0617191D0 (en) * 2006-08-31 2006-10-11 York Pharma Plc Improvements in pharmaceutical compositions
WO2013142383A1 (en) 2012-03-21 2013-09-26 Cosmederm Bioscience, Inc. Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
WO2016141219A1 (en) * 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
WO2020091699A1 (en) 2018-10-31 2020-05-07 Yeditepe Universitesi Use of nano-sized lanthanide borate (dysprosium borate and erbium borate) compounds for wound healing purposes and production method thereof
EP3999076A4 (de) * 2019-07-18 2023-08-09 The Regents of the University of California Zusammensetzungen und verfahren zur behandlung von hauterkrankungen

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE297062C (de) *
GB997975A (en) * 1964-01-31 1965-07-14 Aristotelis Papageorgiou Lambo Pharmaceutical compositions containing a cresol or a mixture of cresols
GB1072355A (en) * 1964-06-17 1967-06-14 Michael Collin Antiseptic and anti-pruretic solution containing camphor
US3519711A (en) * 1967-09-01 1970-07-07 Robert E Svigals Composition and method of treating pruritic conditions of the skin
IE35991B1 (en) * 1971-01-22 1976-07-21 Comprehensive Pharmaceuticals Improvements in or relating to the treatment of diseases of the skin and mucosa
LU65373A1 (de) * 1972-05-17 1973-11-23
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
JPS58501675A (ja) * 1981-10-09 1983-10-06 フエ−リング・ア−ベ− 物質p「きつ」抗質からなる薬材
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8320203D0 (en) * 1983-07-27 1983-09-01 Horrobin D F Anti-viral compositions
DE3338957A1 (de) * 1983-10-27 1985-05-15 Keyhan Dipl.-Ing. 6908 Wiesloch Ghawami Enthaarungsmittel
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
ATE69954T1 (de) * 1985-10-08 1991-12-15 Psori Med Ag Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
US4735802A (en) * 1986-05-05 1988-04-05 Le Bich N Topical dermatological composition and method of treatment
FR2599967B1 (fr) * 1986-06-16 1989-03-31 Bfb Etudes Rech Experimentale Utilisation de sel de zinc et de la vitamine b6 pour enrayer les processus alopeciques et/ou seborrheiques.
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) * 1987-04-02 1988-10-03 Boliden Ab Foerfarande och medel foer konservering av hoe
DE3929411A1 (de) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
FR2644063B1 (fr) * 1989-03-13 1991-06-14 Fabre Pierre Cosmetique Compositions dermatologiques et cosmetologiques a base d'alcoylcarboxamide et de sel de zinc utiles dans le traitement de la dermite seborrheique et/ou des troubles de la seborrhee
CA2014201A1 (en) * 1989-04-26 1990-10-26 Albemarle Corporation Solid non-hygroscopic trialkylamine oxides
DE69007486T2 (de) * 1989-07-31 1994-08-11 Massachusetts Institute Of Technology, Cambridge, Mass. Verwendung von calciumantagonisten für die behandlung von narben.
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
IL95393A0 (en) * 1989-08-18 1991-06-30 John Morris Co Odor-masked and stabilized compositions for treating keratinous tissue,skin conditions,and promoting wound healing
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
US5296476A (en) * 1989-09-08 1994-03-22 Henderson Esther G Skin care compositions
EP0439640B1 (de) * 1990-01-29 1993-09-15 WOGEPHARM GmbH Verfahren zur Herstellung von Mitteln zur Therapie von Hauterkrankungen
EP0451300B1 (de) * 1990-04-10 1994-10-26 Romuald Dr. Kowalski Bariumsulfat-kolloidale Dispersion enthaltende Zusammensetzung
FR2662607B1 (fr) * 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
ATE133657T1 (de) * 1991-07-05 1996-02-15 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
DE69208089T2 (de) * 1991-07-10 1996-08-22 Merck Sharp & Dohme Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
RU2038072C1 (ru) * 1991-11-01 1995-06-27 Государственный российский научно-исследовательский институт органической химии и технологии Крем для защиты кожи от химических веществ и способ его получения
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
DE9211006U1 (de) * 1992-08-17 1993-12-16 Kao Corporation GmbH, 40472 Düsseldorf Mittel zur Haarbehandlung
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
WO1994009798A1 (en) * 1992-10-29 1994-05-11 C-P Technology Limited Partnership Mixtures or complexes containing calcium and sulfate
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1996019182A1 (en) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
ES2192586T3 (es) * 1994-12-21 2003-10-16 Cosmederm Technologies Formulaciones y procedimientos para reducir la irritacion de la piel.
DE4446521A1 (de) * 1994-12-24 1996-06-27 Estee Lauder Inc Mascara-Bürstchen

Also Published As

Publication number Publication date
FR2740341B1 (fr) 1997-12-19
NO964515D0 (no) 1996-10-24
CA2188688A1 (fr) 1997-04-27
ES2155179T3 (es) 2001-05-01
CA2188688C (fr) 2002-12-17
US5866168A (en) 1999-02-02
ATE198276T1 (de) 2001-01-15
DE69611343T2 (de) 2001-04-26
FR2740341A1 (fr) 1997-04-30
NO964515L (no) 1997-04-28
JPH09169657A (ja) 1997-06-30
NO319503B1 (no) 2005-08-22
EP0775492A1 (de) 1997-05-28
EP0775492B1 (de) 2000-12-27

Similar Documents

Publication Publication Date Title
DE69611343D1 (de) Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einem Hautpflegemittel
EP0770392A3 (de) Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einer pharmazeutische Zusammensetzung
EP2338448A3 (de) Antiinflammatorische und antimikrobielle Verwendungen von bioaktiven Glaszusammensetzungen
DE3687099D1 (de) Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
ATE187646T1 (de) Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung
CA2106073A1 (en) Composition for promoting tissue repair and regeneration
DE69700180D1 (de) Kosmetische und/oder dermatologische Zusammensetzung, die mindestens einen Wirkstoffvorläufer und mindestens eine vernetzte Poly(2-acrylamido-2-methylpropansulfonsäure) enthält
HK1046096A1 (en) Solutions and methods for inhibitions of pain, inflammation and cartilage degradation
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
FI963278A0 (fi) Verihiutaleen tuotantoa edistävä aine
GR3021424T3 (en) Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ATE223228T1 (de) Verwendung von latenz assoziierten peptiden in der herstellung eines medikaments zur verbesserung der wundheilung.
IL110808A (en) Pharmaceutical compositions containing aromatic and araliphatic carboxylic acid derivatives for treating light and age-damaged skin and for promoting wound healing and some novel such compounds
CA2058597A1 (en) Wound healing compositions containing fibroblast growth factor and ascorbic acid
ATE142875T1 (de) Methode zur behandlung von haarausfall
EP0770391A3 (de) Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in pharmazeutische Zubereitungen
GB2260702B (en) Improvements relating to the treatment of haemophilia B by subcutaneous injection of factor 1X
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
RU2197263C1 (ru) Способ лечения ран и язвенных дефектов
GB9900325D0 (en) Topical pharmaceutical compositions for healing wounds
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
CA2144127A1 (fr) Composition pour lutter contre les taches et/ou le vieillissement de la peau, ses utilisations
TH14003A (th) การนำส่งยาทางผิวหนังที่ถูกปรับปรุงขึ้น
RU93017673A (ru) Люминесцентный материал и способ приготовления пропиточного раствора

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee